(NASDAQ: XOMA) Xoma Royalty's forecast annual revenue growth rate of 3.48% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.28%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.1%.
Xoma Royalty's revenue in 2026 is $52,149,000.On average, 6 Wall Street analysts forecast XOMA's revenue for 2026 to be $832,466,999, with the lowest XOMA revenue forecast at $602,866,500, and the highest XOMA revenue forecast at $1,150,526,492. On average, 3 Wall Street analysts forecast XOMA's revenue for 2027 to be $637,309,552, with the lowest XOMA revenue forecast at $612,307,682, and the highest XOMA revenue forecast at $656,049,048.
In 2028, XOMA is forecast to generate $742,591,232 in revenue, with the lowest revenue forecast at $713,470,007 and the highest revenue forecast at $764,438,104.